Cellectis (NASDAQ: CLLS) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Insider & Institutional Ownership

16.6% of Cellectis shares are held by institutional investors. Comparatively, 17.1% of AC Immune shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares Cellectis and AC Immune’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectis -217.25% -30.66% -25.66%
AC Immune N/A N/A N/A

Risk & Volatility

Cellectis has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 2.54, indicating that its share price is 154% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cellectis and AC Immune, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis 0 1 5 0 2.83
AC Immune 0 0 2 0 3.00

Cellectis presently has a consensus price target of $39.83, indicating a potential upside of 65.77%. AC Immune has a consensus price target of $21.50, indicating a potential upside of 78.72%. Given AC Immune’s stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than Cellectis.

Valuation & Earnings

This table compares Cellectis and AC Immune’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectis $56.46 million 15.08 -$67.25 million ($2.41) -9.97
AC Immune $23.55 million 29.08 -$7.20 million N/A N/A

AC Immune has lower revenue, but higher earnings than Cellectis.


AC Immune beats Cellectis on 9 of the 11 factors compared between the two stocks.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

AC Immune Company Profile

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.

Receive News & Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related companies with MarketBeat.com's FREE daily email newsletter.